An evergreen life science venture fund located in Copenhagen, Denmark, established in the autumn of 2009 and wholly owned by a large European corporate currently has DKK 1.6 billion in AUM. The firm has an annual investment capacity of approximately 350 – 400m DKK. Investments are typically around €10 million with reserves to follow, and the firm prefers to take above 10% ownership. The firm invests primarily in Europe and in the USA.
The firm invests exclusively in life sciences, focusing on pharmaceuticals. The firm typically prefers to invest at phase I/II but has also made investments at earlier phases of development. The firm is open to opportunities in all therapeutic areas and indications. The firm primarily invest in clinical projects and companies with new technology platforms and are particularly interested in specialist product opportunities.
The firm is oriented towards opportunities in the US and Europe and will take the role of lead investor in Europe. In US the firm prefers to syndicate with well-established VC investors specialized in life sciences. The firm expects to be actively in communication with management and represented on the supervisory board of portfolio companies. The firm is seeking experienced and capable management teams that are committed to resolving the unmet medical needs. Other requirements are a well-defined plan, a strong and durable patent protection, and a sound understanding of the relevant markets and their regulatory frameworks.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment